Bioavailability of Β‐adrenoceptor Blocking Drugs

Johnsson, G.; Regårdh, C G

doi:10.1111/j.1365-2125.1976.tb00361.x

Cited by 2 publications

(1 citation statement)

References 13 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 The t 1/2,abs for atenolol was approximately 7 h, which agrees with an extent of intestinal absorption of 40−50%. 63,64 Atenolol is a BCS class III drug which is mainly absorbed from the small intestine with limited absorption from the colon, 12,46 as shown in an open perfusion study. 12 As 50% of the dose is absorbed only in the small intestine, its transit time agrees with the t 1/2,abs .…”

Section: ■ Introductionmentioning

confidence: 99%

Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development

Lennernäs

2013

Mol. Pharmaceutics

View full text Add to dashboard Cite

Both the development and regulation of pharmaceutical dosage forms have undergone significant improvements and development over the past 25 years, due primarily to the extensive application of the biopharmaceutical classification system (BCS). The Biopharmaceutics Drug Disposition Classification System, which was published in 2005, has also been a useful resource for predicting the influence of transporters in several pharmacokinetic processes. However, there remains a need for the pharmaceutical industry to develop reliable in vitro/in vivo correlations and in silico methods for predicting the rate and extent of complex gastrointestinal (GI) absorption, the bioavailability, and the plasma concentration-time curves for orally administered drug products. Accordingly, a more rational approach is required, one in which high quality in vitro or in silico characterizations of active pharmaceutical ingredients and formulations are integrated into physiologically based in silico biopharmaceutics models to capture the full complexity of GI drug absorption. The need for better understanding of the in vivo GI process has recently become evident after an unsuccessful attempt to predict the GI absorption of BCS class II and IV drugs. Reliable data on the in vivo permeability of the human intestine (Peff) from various intestinal regions is recognized as one of the key biopharmaceutical requirements when developing in silico GI biopharmaceutics models with improved predictive accuracy. The Peff values for human jejunum and ileum, based on historical open, single-pass, perfusion studies are presented in this review. The main objective of this review is to summarize and discuss the relevance and current status of these human in vivo regional intestinal permeability values.

show abstract